In Vivo Targeting of CXCR4-New Horizons

Margret Schottelius1, Ken Herrmann2, Constantin Lapa3

  • 1Translational Radiopharmaceutical Sciences, Department of Nuclear Medicine and of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne (UNIL), 1011 Lausanne, Switzerland.

Cancers
|December 10, 2021
PubMed

Insights

This review highlights C-X-C motif chemokine receptor 4 (CXCR4) theranostics for cancer and inflammation imaging. CXCR4-targeted probes show promise for visualizing immune cell infiltration and predicting disease outcomes.

Area of Science:

  • Nuclear oncology
  • Immunology
  • Medical imaging

Background:

  • C-X-C motif chemokine receptor 4 (CXCR4) is crucial for tumor growth and metastasis.
  • CXCR4 plays a key role in immune cell responses and inflammation.
  • CXCR4-targeted theranostics show clinical potential in oncology.

Purpose of the Study:

  • To review the clinical status of CXCR4-targeted cancer theranostics.
  • To focus on CXCR4-targeted imaging for inflammatory diseases.
  • To discuss the development of CXCR4-targeted imaging agents.

Main Methods:

  • Review of preclinical and clinical studies on CXCR4-targeted imaging.
  • Quantification of tissue infiltration with CXCR4-expressing immune cells.
  • Analysis of imaging probe development for CXCR4.

Main Results:

  • Accumulating clinical evidence supports CXCR4-targeted theranostics in cancer.
  • CXCR4 imaging is gaining attention for visualizing inflammation.
  • The predictive value of CXCR4 imaging signals for disease outcome is discussed.

Conclusions:

  • CXCR4-targeted approaches are valuable for cancer theranostics.
  • CXCR4 imaging offers a promising tool for assessing inflammatory diseases.
  • Advancements in imaging probes are critical for enhancing CXCR4-targeted immune cell imaging.

Related Concept Videos